HLS Therapeutics Inc.
HLS.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 15.54M | 14.09M | 14.52M | 12.47M | 15.86M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.54M | 14.09M | 14.52M | 12.47M | 15.86M |
| Cost of Revenue | 4.22M | 3.67M | 3.72M | 3.04M | 3.92M |
| Gross Profit | 11.32M | 10.41M | 10.80M | 9.43M | 11.94M |
| SG&A Expenses | 6.18M | 6.80M | 6.97M | 6.98M | 6.00M |
| Depreciation & Amortization | 5.43M | 5.51M | 5.86M | 5.92M | 7.05M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.84M | 15.98M | 16.54M | 15.94M | 16.97M |
| Operating Income | -300.00K | -1.89M | -2.03M | -3.47M | -1.11M |
| Income Before Tax | -2.94M | -4.90M | -1.61M | -6.14M | -5.33M |
| Income Tax Expenses | 85.00K | -59.00K | 4.08M | -29.00K | 75.00K |
| Earnings from Continuing Operations | -3.02M | -4.84M | -5.68M | -6.11M | -5.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.02M | -4.84M | -5.68M | -6.11M | -5.40M |
| EBIT | -300.00K | -1.89M | -2.03M | -3.47M | -1.11M |
| EBITDA | 5.09M | 3.62M | 3.83M | 2.45M | 5.88M |
| EPS Basic | -0.20 | -0.15 | -0.18 | -0.19 | -0.17 |
| Normalized Basic EPS | -0.12 | -0.10 | -0.10 | -0.12 | -0.10 |
| EPS Diluted | -0.20 | -0.15 | -0.18 | -0.19 | -0.17 |
| Normalized Diluted EPS | -0.12 | -0.10 | -0.10 | -0.12 | -0.10 |
| Average Basic Shares Outstanding | 30.23M | 31.79M | 31.83M | 31.94M | 31.77M |
| Average Diluted Shares Outstanding | 30.23M | 31.79M | 31.83M | 31.94M | 31.77M |
| Dividend Per Share | -- | -- | -- | -- | 0.00 |
| Payout Ratio | -- | -- | -- | -- | 0.00% |